Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer;Vergleich der Morbidität und Tumorkontrolle nach Behandlung des Prostatakarzinoms mit dreidimensionaler konformaler (3D-CRT 70/74 Gy) und intensitätsmodulierter Strahlentherapie (IMRT 78/82 Gy)

Strahlentherapie und Onkologie

Volumn 191, Issue 4, 2015, Pages 338-346

  Dolezel, Martin ^a,b,c   Odrazka, Karel ^a,b   Zouhar, Milan ^f   Vaculikova, Miloslava ^d   Sefrova, Jana ^e   Jansa, Jan ^f   Paluska, Petr ^f   Kohlova, Tereza ^g   Vanasek, Jaroslav ^a   Kovarik, Josef ^h  

^a Pardubice Regional Hospital   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d Hospital Trutnov   (Czech Republic)

^e Hospital Prachatice   (Czech Republic)

^f UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^g Proton Therapy Center   (Czech Republic)

^h FREEMAN HOSPITAL   (United Kingdom)

Author keywords

3D conformal radiotherapy; Cancer control; Intensity modulated radiotherapy; Prostate cancer; Toxicity

Indexed keywords

AGED; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CZECH REPUBLIC; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GASTROINTESTINAL DISEASES; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MALE; MALE UROGENITAL DISEASES; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION INJURY; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; CZECH REPUBLIC; DISEASE-FREE SURVIVAL; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT;

EID: 84933525368     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0806-y     Document Type: Article

References (39)

1. Hanks GE, Hanlon AL, Epstein B et al (2009) Dose response in prostate cancer with 8–12 years’ follow-up. Int J Radiat Oncol Biol Phys 54:427–435
2. Goldner G, Bombosch V, Geinitz H et al (2009) Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70–74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian–German multicenter phase II trial. Strahlenther Onkol 185:94–100
3. Goldner G, Wachtner S, Wachtner-Gerstner N et al (2006) Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy). Strahlenther Onkol 182:537–542
4. Zelefsky MJ, Pei X, Chou JF et al (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60:1133–1139
5. Zelefsky MJ, Cowen D, Fuks Z et al (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85:2460–2468
6. Cahlon O, Hunt M, Zelefsky MJ (2008). Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol 18:48–57
7. Spratt DE, Pei X, Yamada J et al (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85:686–692
8. Gershkevitsh E, Clark CH, Staffurth J et al (2005) Dose to bone marrow using IMRT techniques in prostate cancer patients. Strahlenther Onkol 181:172–178
9. Kok D, Gill S, Bressel M et al (2013) Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiother Oncol 107:140–146
10. Guckenberger M, Mayer J, Wilbert J et al (2007) Precision of image-guided radiotherapy (IGRT) in six degrees of freedom and limitations in clinical practice. Strahlenther Onkol 183:307–313
11. Guckenberger M, Flentje M (2007). Intensity-Modulated Radiotherapy (IMRT) of localized prostate cancer. Strahlenther Onkol 183:57–62
12. Guckenberger M, Lawrenz I, Flentje M (2014). Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol 190:48–53
13. Pinkawa M, Purch-Lee M, Asadpour B et al (2008) Image-guided radiotherapy for rostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlenther Onkol 184:679–685
14. Zelefsky MJ, Kollmeier M, Cox B et al (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84:125–129
15. Schulze D, Liang J, Yan D et al (2009) Comparison of various online IGRT strategies: the benefits of online treatment plan re-optimization. Radiother Oncol 90:367–376
16. Bauman G, Rumble RB, Chen J et al (2012) Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol) 24:461–473
17. Perna L, Fiorino C, Cozzarini C et al (2009) Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: a comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy. Radiother Oncol 93:57–63
18. Oh CE, Antes K, Darby M et al (1999) Comparison of 2D conventional, 3D conformal, and intensity-modulated treatment planning techniques for patients with prostate cancer with regard to target-dose homogeneity and dose to critical, uninvolved structures. Med Dosim 24:255–263
19. Al-Mamgani A, van Putten WLJ, Heemsbergen WD et al (2008) Update of the Dutch multicenter dose escalation trial of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 72:980–988
20. Dearnaley DP Jovic G Syndikus I (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464–473
21. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74
22. Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294: 1233–1239
23. Alongi F, Fogliata A, Navarria P et al (2012) Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Strahlenther Onkol 188:990–996
24. Dolezel M, Odrazka K, Vaculikova M et al (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 186:197–202
25. Pinkawa M, Holy R, Piroth MD et al (2010) Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 186:600–606
26. Fonteyne V, Villeirs G, Speleers B et al (2008) Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 72:799–807
27. Pearlstein KA, Chen RC (2013). Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. Semin Radiat Oncol 23:182–190
28. Odrazka K, Zouhar M, Petera J et al (2005) Comparison of rectal dose-volume constraints for IMRT prostate treatment planning. Phys Med 21:129–135
29. Hanlon AL, Schultheiss TE, Hunt MA et al (1997) Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 38:59–63
30. Zelefsky MJ, Fuks Z, Happersett L et al (2000) Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55:241–249
31. Al-Mamgani A Heemsbergen WD Peeters ST et al (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73:685–691
32. Michalski JM, Yan Y, Watkins-Bruner D et al (2013) Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiotherapy on the high-dose arm of the RTOG 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 87:932–938
33. Zelefsky MJ Levin EJ Hunt M (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129
34. Sharma NK, Li T, Chen DY et al (2011) Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 80:437–444
35. Sheets NC, Goldin GH, Meyer AM et al (2012) Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307:1611–1620
36. Vora SA, Wong WW, Schild SE et al (2007) Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68:1053–1058
37. Heemsbergen WD, Al-Mamgani A, Slot A et al (2014) Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 110:104–109
38. Kupelian PA, Langen KM, Willoughby TR et al (2008) Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol 18:58–66
39. Paluska P, Hanus J, Sefrova J et al (2012) Utilization of cone-beam CT for offline evaluation of target volume coverage during prostate image-guided radiotherapy based on bony anatomy alignment. Reports of Practical Oncology and Radiotherapy 17:134–140